On October 20, 2020 Aileron Therapeutics (Nasdaq: ALRN) reported that it will host a conference call and live webcast to discuss results from a Phase 1b proof-of-concept study of ALRN-6924 on Monday, October 26, 2020 at 8:30 a.m. ET (Press release, Aileron Therapeutics, OCT 20, 2020, http://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-host-conference-call-discuss-results-phase [SID1234568681]). As previously announced by Aileron, the Phase 1b clinical data will be presented in a late-breaking poster presentation during the upcoming 32nd EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Annual (ENA 2020) Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24 – 25, 2020. The abstract entitled, "Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDM2/MDMX inhibitor ALRN-6924," (LBA96) will be presented starting Saturday, October 24 at 10:00 a.m. CEST (4:00 a.m. ET), on the ENA 2020 website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ALRN-6924 is the first and only chemoprotective therapy in clinical development to utilize a biomarker strategy by treating patients with p53-mutated cancers with the goal of limiting chemotherapy-induced toxicities and side effects. ALRN-6924, an investigational first-in-class MDM2/MDMX dual inhibitor, is a cell-permeating peptide drug that works intracellularly, activating wild-type p53 to selectively shield normal, healthy cells from chemotherapy in patients who harbor p53 mutations without interrupting chemotherapy’s targeting of cancer cells.

A live audio webcast of Aileron’s conference call will be available on the Investors section of Aileron’s website at View Source To access the call, please dial 877-705-6003 (domestic) or +1 201-493-6725 (international) five minutes prior to the start time and reference conference ID 13712133. The webcast will be archived on Aileron’s site for one year.

On October 20, 2020 Immunomic Therapeutics, Inc. (ITI) reported that it will be presenting at the 5th International Virtual Conference on Cancer Research & Development (Press release, Immunomic Therapeutics, OCT 20, 2020, View Source [SID1234568680]). On Monday, October 26, 2020, Chief Executive Officer at ITI, Dr. Bill Hearl, will be presenting a talk titled, "UNITE Platform, A Direct Antigen Presentation Approach in Oncology." Dr. Hearl will discuss ITI’s investigational platform technology, the company’s lead program and its preliminary data, as well as the company’s future focus.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Panel details are as follows:

Title: UNITE Platform, A Direct Antigen Presentation Approach in Oncology

Panel Category: Cancer Immunology

Panel Date and Time: Monday, October 26, 2020 1:10-1:35 PM ET

Location: Cancer R&D Virtual Symposium

About UNITE

ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein 1, an endogenous protein in humans, for immune processing. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach puts UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in a Phase II clinical trial as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP1 nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.

On October 20, 2020 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience, reported the presentation of new preclinical data on its VISTA antagonist antibodies at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Special Conference on Tumor Immunology and Immunotherapy (Press release, Kineta, OCT 20, 2020, View Source;utm_medium=rss&utm_campaign=kineta-presents-new-preclinical-data-on-its-vista-antagonist-antibodies-at-the-american-association-for-cancer-research-virtual-special-conference-on-tumor-immunology-and-immunotherapy [SID1234568673]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thierry Guillaudeux, PhD, Vice President Immuno-oncology at Kineta, presented the new preclinical data on the company’s fully human anti-VISTA antibodies during the Innate and Adaptive Checkpoints plenary session. Key findings from the presentation include the following:

Kineta’s anti-VISTA antibodies carry unique sequences and the selected lead candidates exhibit potencies in the subnanomolar range
Kineta’s human anti-VISTA antibodies are highly specific and cross-react with cyno-VISTA but not mouse-VISTA
VISTA antagonist antibody induces strong anti-tumor response as a single agent or in combo-therapies with anti-PD-L1 or anti-CTLA-4 in CT26 tumor models
VISTA antagonist antibody activates dendritic cells in the blood and reduces MDSCs
"We are very pleased with the development of our new anti-VISTA antibody program and the selection of our lead candidates" said Thierry Guillaudeux. "VISTA is a unique immuno-oncology target for the treatment of non-immunogenic tumors, with a central role in re-programming the tumor microenvironment to turn cold tumors hot."

VISTA is a key driver of the immunosuppressive tumor microenvironment (TME) and is overexpressed on myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs). It is a critical myeloid cell immune-checkpoint, and VISTA blockade can reprogram suppressive myeloid cells and reactivate antitumor immune function. Blocking VISTA activates an immune cell cascade that increases T cell effector functions to drive an efficient anti-tumor response. Preclinical studies have demonstrated single agent anti-VISTA activity but also demonstrate that targeting VISTA in combination with PD-1, PD-L1 or CTLA-4 can significantly improve the efficacy of those checkpoint inhibitors.

Presentation Details:

Title: Highly potent fully human anti-VISTA antibodies – A new target checkpoint inhibitor against immunosuppressive myeloid cells
Session Title: Innate and Adaptive Checkpoints
Date/Time: October 19, 2020, 2:20 PM – 2:29 PM Eastern
Presenter: Thierry Guillaudeux, PhD

On October 20, 2020 Oasmia Pharmaceutical’s CEO, Dr Francois Martelet reported that it will present at the Bio Europe’s Digital conference October 26-29, 2020 and take part in partnering meetings (Press release, Oasmia, OCT 20, 2020, View Source [SID1234568672]). The presentation will be made available on demand on the Bio Europe Digital website and accessible to attendees registered for the event. The presentation will also be uploaded onto Oasmia’s website following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 20, 2020 Carina Biotech and UniSA reported they have developed a new device to improve cancer immunotherapies (Press release, Carina Biotech, OCT 20, 2020, View Source [SID1234568669]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our researchers at the University of South Australia have developed a novel approach based on microfluidic technology to "purify" the immune cells of patients in the fight against cancer.

UniSA’s Future Industries Institute PhD student Mona Elsemary (pictured) has developed a microfluidic approach to purify chimeric antigen receptor (CAR-T) cells, the bioengineered immune cells that are the basis of groundbreaking cellular immunotherapy – a transformative cancer therapy that harnesses the power of a patient’s immune system to fight their cancer.

Ms Elsemary’s work is part of Carina Biotech’s CAR-T development platform, which aims to produce effective treatments for solid cancers. Ms Elsemary will present her work tomorrow at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Conference on Tumor Immunology and Immunotherapy.

"CAR-T therapy has produced some remarkable results against blood cancers and there is a huge international research effort underway to transform this success into producing CAR-T treatments for solid cancers," Ms Elsemary says.

"However, the CAR-T manufacturing process continues to be hindered by significant barriers and high costs – preventing the full potential of this life-saving therapy being reached."

Such problems include the presence of non-viable cells and debris in the formulation and the presence of cryoprotectants (e.g., dimethyl sulfoxide or DMSO), typically used for the freezing and storage of CAR-T cell products.

The presence of dead cells can cause potentially severe side effects in recipients, and the US Federal and Drug Administration (FDA) has set strict viability specifications for CAR-T products, with approximately 10% of patients not receiving their treatment due to failure in meeting them.

The presence of cryoprotectants in final CAR-T products can also cause severe allergic reactions and toxic side effects in some patients.

"Current commercial CAR-T cell products still contain significant amounts of DMSO," Ms Elsemere says. "Therefore, there is a significant need for a method that effectively purifies CAR T cells prior to infusion to patients."

The approach was developed by the University of South Australia team led by Prof Benjamin Thierry in collaboration with Assoc Prof Majid Warkiani at the University Technology Sydney, and could achieve, within 30 minutes, depletion of over 70% of dead cells in the CAR T products, leading to an average of 20% increase in cell viability.

In addition, over 90% of the cryoprotectant DSMO is removed – all with no detrimental effect on the quality and functionality of the cells.

Ms Elsemary’s research could greatly benefit patients by reducing both manufacturing cost and side-effects commonly associated to CAR T cell therapy.